Comparison of exercise, dobutamine-atropine and dipyridamole-atropine stress echocardiography in detecting coronary artery disease by Nedeljkovic, Ivana et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Cardiovascular Ultrasound
Open Access Research
Comparison of exercise, dobutamine-atropine and 
dipyridamole-atropine stress echocardiography in detecting 
coronary artery disease
Ivana Nedeljkovic*, Miodrag Ostojic, Branko Beleslin, Ana Djordjevic-Dikic, 
Jelena Stepanovic, Milan Nedeljkovic, Sinisa Stojkovic, Goran Stankovic, 
Jovica Saponjski, Zorica Petrasinovic, Vojislav Giga and Predrag Mitrovic
Address: University Institute for Cardiovascular Diseases, Department for Diagnostic and Catheterization Laboratories, Clinical Center of Serbia, 
Serbia and Montenegro
Email: Ivana Nedeljkovic* - ivannanedeljkovic@yahoo.com; Miodrag Ostojic - miodrag.ostojic@kcs.sc.yu; 
Branko Beleslin - branko.beleslin@kcs.ac.yu; Ana Djordjevic-Dikic - scali@bitsyu.net; Jelena Stepanovic - jelena.stepanovic@kcs.ac.yu; 
Milan Nedeljkovic - milanned@hotmail.com; Sinisa Stojkovic - sinisa.stojkovic@kcs.ac.yu; Goran Stankovic - gorastan@hotmail.com; 
Jovica Saponjski - jovica.saponjski@kcs.ac.yu; Zorica Petrasinovic - zorica.petrasinovic@kcs.ac.yu; Vojislav Giga - giga@eunet.yu; 
Predrag Mitrovic - predragm@eunet.yu
* Corresponding author    
Abstract
Background: Dipyridamole and dobutamine stress echocardiography testing are most widely
utilized, but their sensitivity remained suboptimal in comparison to routine exercise stress
echocardiography. The aim of our study is to compare, head-to-head, exercise, dobutamine and
dipyridamole stress echocardiography tests, performed with state-of-the-art protocols in a large
scale prospective group of patients.
Methods: Dipyridamole-atropine (Dipatro: 0.84 mg/kg over 10 min i.v. dipyridamole with addition
of up to 1 mg of atropine), dobutamine-atropine (Dobatro: up to 40 mcg/kg/min i.v. dobutamine
with addition of up to 1 mg of atropine) and exercise (Ex, Bruce) were performed in 166 pts. Of
them, 117 pts without resting wall motion abnormalities were enrolled in study (91 male; mean age
54 ± 10 years; previous non-transmural myocardial infarction in 32 pts, angina pectoris in 69 pts
and atypical chest pain in 16 pts). Tests were performed in random sequence, in 3 different days,
within 5 day period under identical therapy. All patients underwent coronary angiography.
Results: Significant coronary artery disease (CAD; ≥50% diameter stenosis) was present in 69 pts
(57 pts 1-vessel CAD, 12 multivessel CAD) and absent in 48 pts. Sensitivity (Sn) was 96%, 93% and
90%, whereas specificity (Sp) was 92%, 92% and 87% for Dobatro, Dipatro and Ex, respectively (p
= ns). Concomitant beta blocker therapy did not influence peak rate-pressure product and Sn of
Dobatro and Dipatro (p = ns).
Conclusion: When state-of-the-art protocols are used, dipyridamole and dobutamine stress
echocardiography have comparable and high diagnostic accuracy, similar to maximal post-exercise
treadmill stress echocardiography.
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Background
Exercise stress echocardiography is more sensitive and
specific for detecting inducible ischemia than exercise
electrocardiography testing alone [1-4]. Dipyridamole
and dobutamine stress echocardiography testing are most
widely utilized, but their sensitivity remained suboptimal
in comparison to routine exercise stress echocardiography
[5,6]. This diagnostic challenge provoked development of
stress protocols including addition of atropine [7-12]. The
objective of this study was to assess in head-to-head fash-
ion diagnostic value of dipyridamole-atropine, dob-
utamine-atropine and exercise stress echocardiography in
the same group of patients presented for evaluation of cor-
onary artery disease.
Methods
Study population
Between January and July 2004, 166 consecutive patients
referred for coronary angiography were evaluated. Of
them, only 117 (91 male, 26 female; mean age 54 ± 10
years) patients without resting wall motion abnormalities
were enrolled in the study. Exclusion criteria were: pres-
ence of left ventricular wall motion abnormality at base-
line, heart failure, left bundle branch block, unstable
angina, congenital or valvular heart disease, severe hyper-
tension (systolic ≥180 mmHg and diastolic pressure ≥110
mmHg), serious arrhythmias and chronic obstructive pul-
monary disease.
Informed consent was obtained from all patients. They
underwent exercise, and pharmacological stress echocar-
diography. Previous non-transmural myocardial infarc-
tion was present in 32 patients, 69 had angina pectoris
and 16 patients experienced atypical chest pain.
The study was approved by the Institutional Review Board
of the Institute of Cardiovascular Diseases in Belgrade.
Concomitant beta blockers were used in 34% (40/117),
calcium antagonists in 37% (44/117) and nitrates in 45%
(53/117) of patients. Teophylline, caffeine-containing
products, and dipyridamole preparations were not
allowed for at least 12 hours before testing.
Patients performed stress testing in 3 different days in ran-
dom sequence within 5 day period, at least 14 days after
uncomplicated myocardial infarction.
Stress protocols
Exercise echocardiography (Ex) was performed according to
maximal Bruce treadmill protocol.
Dobutamine-atropine (Dobatro)
Dobutamine was infused in 3-minutes dose increments,
starting from 5 to 40 mcg/kg/min. In echocardiography
negative patients, atropine was added (in 4 divided doses
up to a maximum of 1 mg of atropine) to the continuing
40 mcg/kg/min dobutamine infusion [11].
Dipyridamole-atropine (Dipatro)
Dipyridamole was infused at a dose of 0.56 mg/kg over 4
min, followed with 4 min of no dose and then, if the test
was still negative, 0.28 mg/kg in 2 min. In dipyridamole
echocardiography negative patients, 3 min after the end of
infusion, atropine was given in 4 divided doses up to a
maximum of 1 mg of atropine [12].
The test was considered positive in the presence of obvi-
ous left ventricular regional wall motion abnormality. The
other reasons for test interruption were: peak atropine
dose (for pharmacological tests), achievement of maximal
age predicted heart rate, significant ST segment depression
or elevation, severe chest pain, exercise-limiting dyspnea,
fatigue and/or claudication, symptomatic hypotension
(decrease in systolic blood pressure >20 mmHg) or hyper-
tension (>220/120 mmHg), severe arrhythmias or intoler-
able side effects of administered drugs. Intravenous
aminophylline (250 mg) was given after cessation of
Dipatro test, and beta blockers (metoprolol 5 mg) or
nitroglycerin if required.
A 12-lead electrocardiogram monitoring was performed
continuously and recorded at baseline, at the end of each
stage and during recovery period accompanied with blood
pressure recordings. Rate pressure product was calculated
by multiplying systolic blood pressure and heart rate.
Echocardiographic analysis
Two-dimensional echocardiography was performed with
the patient in the left lateral decubitus position. Standard
apical and parasternal views were recorded, facilitating the
analysis from the off line digitized videotapes (Image
View, ATL). We used 16-segment left ventricular model
[13]. Segmental wall motion was evaluated using stand-
ard method: normal – 1, hypokinetic – 2, akinetic – 3, or
dyskinetic – 4 [13]. Wall motion score index was derived
for rest and peak stress tests. Video tapes were analyzed
independently by two experienced observers unaware of
patients' data or other tests results with overall agreement
of 92%. By subgroup analysis, the interobserver agree-
ment was 93%, 94% and 90% for Dobatro, Dipatro, and
Ex. In case of discrepancy decision was made by consen-
sus.
Coronary angiography and quantitative angiographic 
analysis
All patients underwent selective coronary angiography
according to Judkin's technique, within one week of stress
echocardiography tests. Angiograms were analyzed using
quantitative coronary angiography (MEDIS CMS, Leiden,Cardiovascular Ultrasound 2006, 4:22 http://www.cardiovascularultrasound.com/content/4/1/22
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The Netherlands) by observers unaware of the patient's
data. Significant coronary artery stenosis was considered
as ≥50% diameter stenosis present in at least one major
epicardial coronary vessel.
Statistical analysis
The data are expressed as mean ± SD. Comparison of con-
tinuous variables was performed using ANOVA As, New-
man-Keuls procedure and t  test where appropriate,
whereas dichotomous variables were compared using chi-
square (McNemar-s test for paired proportions). A coeffi-
cient of correlation (r) was used to compare peak wall
motion score index of different tests. Confidence intervals
were calculated according to standard formulas (95%CI)
as well as sensitivity, specificity and diagnostic accuracy.
Calculation of sensitivity, specificity and diagnostic accu-
racy were performed according to standard formulas. A p
value less than 0.05 was considered statistically signifi-
cant.
Results
Angiographic characteristics
Coronary artery disease was present in 69 patients: one-
vessel coronary artery disease was present in 57 patients,
12 patients had multi-vessel coronary artery disease. The
distribution of lesions were: left anterior descending – 50
patients, circumflex artery – 15 patients, and right coro-
nary artery – 16 patients.
Feasibility, safety and hemodynamic changes
Feasibility was 95% and 97% for Dobatro and Dipatro (p
= ns), respectively. Limiting side effects occurred in 6 and
in 4 patients during Dobatro and Dipatro, including non-
sustained ventricular tachycardia and short run of
supraventricular tachycardia in the absence of myocardial
ischemia. They disappeared after cessation of the test or
after administration of specific antidote.
Limiting side effects occurred in 17 patients (14%) during
Ex in the absence of diagnostic end point and consisted of
serious ventricular and supraventricular rhythm distur-
bances, severe chest pain, hypertensive response and
fatigue. Thus, feasibility of Ex was 85%. There was no sig-
nificant difference in feasibility of all three tests (p = ns for
all intergroup differences). There were no late complica-
tions in the ensuing hours after finishing the tests.
Hemodynamic changes during stress echocardiography
tests are presented in Table 1.
Diagnostic value of stress echocardiography
Atropine was added to dobutamine in 69% (81/117) of
patients and to dipyridamole in 68% (80/117) of
patients. Stress-induced wall motion abnormalities
appeared in 70, 68 and 68 patients during Dobatro, Dipa-
tro and Ex, respectively. The sensitivity was 96%, 93% and
90% for Dobatro, Dipatro and Ex in detection of myocar-
dial ischemia (p = ns for Ex vs. Dobatro vs. Dipatro) (Fig-
ure 1). Specificity was 92% both for Dobatro and Dipatro,
and 87% for Ex (p = ns for all intergroup differences).
Diagnostic accuracy was: 94% for Dobatro, 92% for Dipa-
tro and 90% for Ex, respectively (p = ns for Ex vs. Dobatro
vs. Dipatro).
Dobatro, Dipatro and Ex provoked significant change
from the rest to peak stress WMSI (1.32 ± 0.18, 1.31 ± 0.17
and 1.28 ± 0.18, for Dobatro, Dipatro, and Ex; p = ns for
all), with significant correlation (p < 0.0001) of peak
WMSI between all tests.
Single vs. multivessel CAD: The sensitivity of stress in
detection of one-vessel coronary artery disease was 95%
for Dobatro and 95% for Dipatro and 93% for Ex (p = ns
for Ex vs. Dobatro, and Ex vs. Dipatro). The sensitivity for
detection of multivessel coronary artery disease was 100%
for Dobatro and Dipatro and 92% for Ex (p = ns).
The impact of concomitant beta – blocker therapy on 
stress echocardiographic results
Forty (34%) patients received concomitant beta blocker
therapy (34 with coronary artery disease). There was sig-
nificant difference between patients with (BB+) and with-
out beta-blocker therapy (BB-) in the peak heart rate for
Dob, Dip, and Ex (p < 0.001), whereas addition of atro-
pine excluded significant influence of beta-blocker ther-
Table 1: Peak hemodynamic data during dobutamine, dobutamine-atropine, dipyridamole, dipyridamole-atropine and exercise stress 
tests.
Dob Dobatro Dip Dipatro Ex
Heart rate, beat/min 110 ± 27 138 ± 25* 91 ± 15 125 ± 25* 148 ± 22**
Systolic blood pressure, mmHg 155 ± 20 160 ± 30* 138 ± 22 158 ± 20* 182 ± 24**
Diastolic blood pressure, mmHg 98 ± 15 103 ± 10 90 ± 9 97 ± 12 109 ± 14**
PRR, mmHg × beat/min/100 170 ± 64 221 ± 60* 126 ± 32 198 ± 59* 348 ± 61**
Values are given as mean ± SD. Dob indicates dobutamine; Dobatro, dobutamine-atropine; Dip, dipyridamole; and Dipatro, dipyridamole-atropine; 
RPP, rate-pressure product. Asterisk indicates significant difference for Dobatro vs. Dob, and Dipatro vs. Dip (p < 0.0001). Two asterisks indicate 
significant difference between Ex and other tests (p < 0.0001 for all).Cardiovascular Ultrasound 2006, 4:22 http://www.cardiovascularultrasound.com/content/4/1/22
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apy on peak heart rate. Rate-pressure product at baseline
and peak stress tests in patients with (BB+) and without
(BB-) concomitant beta-blocker therapy are presented in
Table 2.
Atropine was added to dobutamine in 75% of patients in
BB+ (34/40) and in 61% in BB- group (47/77), and to
dipyridamole in 85% of patients in BB+ (34/40) and 60%
(46/77) in BB- group. Addition of atropine resulted in
similar sensitivity (Dobatro: BB+ 86% vs. BB- 89%, p = ns;
Dipatro: BB+ 88% vs. BB- 92%, p = ns). However, sensitiv-
ity of Ex was significantly affected by beta-blocker therapy
(BB+ 80% vs. BB- 92%, p < 0.01) (Figure 2).
Discussion
This study represents for the first time direct comparative
evaluation of dobutamine-atropine and dipyridamole-
atropine – with exercise stress echocardiography per-
formed in the same group of patients. Dipyridamole-atro-
pine and dobutamine-atropine stress echocardiography
have comparable and high diagnostic accuracy, similar to
maximal post-exercise treadmill stress echocardiography.
In addition, dipyridamole-atropine and dobutamine-
atropine stress echocardiography testing overcomes the
effects of concomitant beta-blocker therapy reaching high
and comparable diagnostic value.
Our results are comparable with previous findings show-
ing that atropine coadminitsration significantly improved
sensitivity in dobutamine and dipyridamole negative
patients [11,12]. In addition, Pingitore et al. have shown,
in comparative study with dobutamine-atropine and
dipyridamole-atropine, that both tests have comparative
sensitivity of 84% and 82%, respectively, without signifi-
cant difference between them [14].
It has been shown that beta-blocker therapy can signifi-
cantly influence results of stress echocardiography tests if
routine doses are employed. Beta-blockers are known to
protect from exercise induced ischemia [15]. They also
affect the results of dipyridamole stress echocardiography,
despite the fact that hemodynamic profile is at least
affected by dipyridamole [16]. In our study, addition of
atropine induced significant increase in heart rate, systolic
blood pressure and rate pressure product as well as
increase of diagnostic accuracy in comparison to dob-
utamine and dipyridamole alone regardless of beta
blocker therapy. In comparison to exercise stress echocar-
diography testing, atropine coadministration resulted in
similar sensitivity and specificity of dobutamine-atropine
and dipyridamole-atropine stress echocardiography in
both groups of patients. Thus, atropine factor in pharma-
cological stress echocardiography testing can overcome
the effects of beta-blocker therapy, as it has been shown in
previous studies [17,18].
Pathophysiological mechanisms
We used three tests with different mechanisms of provok-
ing myocardial ischemia through a) an increase in oxygen
demand, exceeding the fixed supply – dobutamine and
exercise; and b) flow maldistribution, due to inappropri-
ate coronary artery vasodilatation. Atropine superimposes
a marked chronotropic stress to dipyridamole and dob-
utamine increasing oxygen demand, decreasing, at the
Sensitivity, specificity and diagnostic accuracy of stress  echocardiography tests Figure 1
Sensitivity, specificity and diagnostic accuracy of 
stress echocardiography tests. Bar graph showing sensi-
tivity (Sn), specificity (Sp) and diagnostic accuracy (Acc) of 
dobutamine-atropine (Dobatro), dipyridamole-atropine 
(Dipatro) and exercise (Ex) stress echocardiography tests. 
There was no statistically significant difference between 
three tests. Asterisk indicates significant difference between 
stress tests (p < 0.01).
Table 2: Rate-pressure product at baseline and peak stress tests in patients with (BB+) and without (BB-) concomitant beta-blocker 
therapy
RPP (mmHgxbpm/
100)
baseline Dob Dobatro Dip Dipatro Ex
BB+ group 110 ± 25 167 ± 27 213 ± 58 135 ± 10 199 ± 37 233 ± 22
BB- group 123 ± 40* 205 ± 20 230 ± 53 145 ± 12* 210 ± 40 389 ± 77*
RPP indicates rate-pressure product; Dob indicates dobutamine; Dobatro, dobutamine-atropine; Dip, dipyridamole; Dipatro, dipyridamole-
atropine; Values are given as mean ± SD. Asterisk indicates significant difference between stress tests (p < 0.001).Cardiovascular Ultrasound 2006, 4:22 http://www.cardiovascularultrasound.com/content/4/1/22
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same time, myocardial oxygen supply by shortening the
diastole whose duration is important for perfusion in the
presence of maximal vasodilatation [19] and increasing
the ischemic potential of stress echocardiography [11,12].
Comparison with previous studies
Several meta-analytic comparisons of echocardiographic
stressors have been performed in the past [20-23]. They
unanimously reached the conclusion that dipyridamole is
more specific than dobutamine and exercise, and exercise
and dobutamine are more sensitive than dipyridamole for
noninvasive detection of coronary artery disease affecting
the recent cardiology guidelines [4] and standard text-
book knowledge [24], which suggests to use dipyridamole
stress in combination with perfusion scintigraphy and
consider only dobutamine stress as a suitable pharmaco-
logical stress to be combined with echocardiography.
However, this conclusion conflicts the results of present
study. The reason of this apparent discrepancy is the fact
that with the vasodilator stress echocardiography, one
needs the high dose protocol with atropine to optimize
the diagnostic sensitivity. The same result can be
obtained, without atropine, by using the high dose over a
shorter infusion time of dipyridamole: the so called accel-
erated protocol [25]. As a matter of fact, the 1998. Guide-
lines of the American Society of Echocardiography clearly
recommended high dose + atropine, as the standard pro-
tocol to achieve optimal accuracy with dipyridamole
stress echocardiography [13]. Accordingly, if we consider
only the literature with state-of-the-art dipyridamole pro-
tocols (with accelerated infusion or with atropine coad-
ministration), the conclusions of the guidelines and
recent textbook recommendations clash against available
evidence. Two previous reports [26,27] comparing accel-
erated dipyridamole versus dobutamine stress echocardi-
ography tests, and 2 additional reports [14,28] comparing
dipyridamole-atropine stress echocardiography versus
dobutamine stress echocardiography, have reached con-
sistent conclusion of each individual study – cumulative
analysis has shown that dipyridamole had a better specif-
icity and the same sensitivity in comparison with high
dose dobutamine stress echo. These results of the pub-
lished literature, as well as the results of the present study,
represent a weight of evidence which may influence cur-
rent guidelines and recent cardiology textbooks state-
ments. When state of the art protocols are used, either
dobutamine or dipyridamole provide excellent and com-
parable diagnostic sensitivity and overall accuracy.
Study limitations
The study group was derived from patients referred for
coronary angiography and angioplasty, so large majority
of patients had the one-vessel coronary artery disease. The
use of a qualitative assessment of wall motion during
stress echocardiography is a limitation of this technique,
although qualitative assessment of regional wall motion
by trained observers remains the only clinically applied
method in stress echocardiography.
Conclusion
When state-of-the-art protocols are used, dipyridamole
and dobutamine stress echocardiography have compara-
ble and high diagnostic accuracy, similar to maximal post-
exercise treadmill stress echocardiography. In addition,
dipyridamole-atropine and dobutamine-atropine stress
echocardiography testing overcome the effects of concom-
itant beta-blocker therapy reaching high and comparable
diagnostic value.
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